In cholangiocarcinoma, pharmacological inhibition of PLK2 via BI6727 and PLK2 knockdown degrade the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) which represents a survival factor in this malignancy, and lead to apoptosis and tumor suppression in vivo [180]. Here, PLK2 is linked to cholangiocarcinoma.